Breaking News Instant updates and real-time market news.

SHOP

Shopify

$130.13

7.66 (6.25%)

, CVSI

CV Sciences

$0.00

(0.00%)

11:22
10/25/18
10/25
11:22
10/25/18
11:22

Shopify platform 'natural fit' for recreational use cannabis, COO says

Shopify (SHOP) COO Harley Finkelstein said on this morning's earnings call, "In October, Shopify Plus entered new retail territory in Canada, when cannabis was legalized here on October 17. While we don't normally call out specific verticals, we have been fielding several questions about this one given how new it is and the fact it is a highly regulated industry. We have actually already been the platform of choice for licensed producers of medical cannabis in Canada for years. So with the legalization of cannabis for recreational use, Shopify was a natural fit. We are now powering recreational cannabis sales for the largest Canadian provincial governments as well as the leading licensed producers and private retailers. These retailers recognize that Shopify's technology is uniquely positioned to help them adapt to the demands of regulators and fulfill key requirements. We are proud of what we've been able to accomplish in a tight period of time, given the complexities in introducing a new and regulated industry." Shares of Shopify, a multi-channel commerce platform, are up 7%, or $8.55, to $130.78 following this morning's Q3 earnings report. Publicly traded companies in the cannabis space include Aurora Cannabis (ACB), CV Sciences (CVSI), CannTrust Holdings (CNTTF), Canopy Growth (CGC), Cronos Group (CRON), General Cannabis (CANN), India Globalization Capital (IGC) and Tilray (TLRY).

SHOP

Shopify

$130.13

7.66 (6.25%)

CVSI

CV Sciences

$0.00

(0.00%)

TLRY

Tilray

$109.99

0.98 (0.90%)

CRON

Cronos Group

$7.96

0.34 (4.46%)

CANN

General Cannabis

$0.00

(0.00%)

IGC

India Globalization Capital

$2.69

0.09 (3.46%)

CGC

Canopy Growth

$39.00

1.27 (3.37%)

ACB

Aurora Cannabis

$7.12

-0.135 (-1.86%)

CNTTF

CannTrust Holdings

$0.00

(0.00%)

  • 25

    Oct

  • 13

    Nov

  • 13

    Nov

  • 14

    Nov

  • 29

    Nov

SHOP Shopify
$130.13

7.66 (6.25%)

10/17/18
BARD
10/17/18
NO CHANGE
BARD
Pressure on Shopify around China shipping overblown, says Baird
Baird analyst Colin Sebastian noted that Shopify was under a lot of pressure after a New York Times report that the Trump administration plans to withdraw from the Universal Post Office Treaty, which had previously allowed Chinese merchants to ship packages to the US at steeply discounted rates. Sebastian called the fears " way overblown," noting that Shopify's total exposure in China is low, and maintained an Outperform rating with a $165 price target on Shopify shares.
09/17/18
09/17/18
NO CHANGE

Fly Intel: Today's top analyst calls on Wall Street
Check out today's top analyst calls from around Wall Street, compiled by The Fly. LULULEMON UPGRADED TO OUTPERFORM: Wells Fargo analyst Ike Boruchow upgraded Lululemon (LULU) to Outperform from Market Perform, stating that while the brand's current strength is "evident to essentially everyone," his recent meetings with management lead him to believe that its "industry leading" momentum is likely sustainable through the second half of this year and well into 2019. While admitting to being "late to the party," Boruchow said he sees meaningful outperformance and upward revisions being ahead for the athletic apparel company. He raised his price target on Lululemon shares to $200 from $144. In late morning trading, Lululemon shares are higher by 2.3%. NOMURA UPGRADES BROADCOM TO BUY: Nomura Instinet analyst Romit Shah upgraded Broadcom (AVGO) to Buy from Neutral and raised his price target for the shares to $300 from $225. The analyst says the "so many positive takeaways from earnings" have forced him to take a more constructive stance on the shares. GOLDMAN SWAPS CONVICTION BUY ON MASTERCARD, VISA: Goldman Sachs analyst James Schneider added MasterCard (MA) to his firm's Conviction List while maintaining a Buy rating on the shares. The analyst also upped his price target for the stock to $260 from $230. Goldman Sachs analyst James Schneider removed Visa (V) from his firm's Conviction List but maintains a Buy rating on the shares with an unchanged price target of $160. The analyst, who continues to see upside to Street estimates, cites the recent share outperformance for the removal. MORGAN STANLEY INITIATES CONSUMER STAPLES: Morgan Stanley analyst Dara Mohsenian assumed Kraft Heinz (KHC) with an Underweight and $52 price target, as he believes it topline growth will likely trail food peers. In late morning trading, Kraft Heinz shares were down almost 2%. The analyst also assumed coverage of Mondelez (MDLZ), General Mills (GIS), and Kellogg (K) with Equal Weight ratings. KEYBANC SEES CANNABIS AS DRIVER FOR SHOPIFY: KeyBanc analyst Monika Garb said she is a buyer of Shopify (SHOP), as the company has "ample" growth opportunities ahead, and she sees potential upside to her above-consensus estimates. She expects that recreational sales of cannabis in Canada could be a GMV and revenue driver and further benefit Shopify's business momentum. Garb maintained an Overweight rating and $182 price target on the shares.
10/01/18
JEFF
10/01/18
INITIATION
Target $175
JEFF
Hold
Shopify initiated with a Hold at Jefferies
Jefferies analyst Samad Samana started Shopify with a Hold rating and $175 price target. The analyst expects Shopify to continue to post "healthy growth for years to come," but is cautious on the stock given the greater than 280% increase since start of 2017. The valuation multiple approaching all-time highs, Samana tells investors in a research note
10/10/18
KEYB
10/10/18
NO CHANGE
KEYB
Shopify, Salesforce should be bought on October pullback, says KeyBanc
KeyBanc analyst Brent Bracelin notes that the 55 largest SaaS stocks had an incredible run through the end of Q3, as the group benefited from robust secular tailwinds and multiple expansion with forward EV/S levels increasing by two full turns above the five-year average. That said, the "Big Chill" has quickly set in during the first nine days of October as the group is down 11% this month and 21% from the highs, on average, he adds. The analyst has identified eight high-quality SaaS stocks that he would buy on the October pullback based on attractive risk-reward and growth profiles looking out into 2020, namely Shopify (SHOP), Salesforce (CRM), Twilio (TWLO), Wix.com (WIX), Zendesk (ZEN), BlackLine (BL), Avalara (AVLR), and Mindbody (MB).
CVSI CV Sciences
$0.00

(0.00%)

10/17/18
MSCO
10/17/18
NO CHANGE
MSCO
Morgan Stanley says pot legalization could pose risk to Canadian auto insurers
Morgan Stanley analyst Kai Pan noted that academic studies do not agree on the potential impact on car accidents from legalized recreational use of marijuana, but he still believes Canada's legalization could pose a risk to Canadian auto insurers. IFC, the largest auto insurer in Canada, is not immune to this challenge but given its long-term outperformance versus peers and strong claims management, Pan thinks the company should be better positioned in addressing this challenge, he tells investors. Publicly traded companies in the cannabis space include Aurora Cannabis (ACBFF), CV Sciences (CVSI), CannTrust Holdings (CNTTF), Canopy Growth (CGC), Cronos Group (CRON), General Cannabis (CANN), India Globalization Capital (IGC) and Tilray (TLRY).
09/20/18
STFL
09/20/18
NO CHANGE
STFL
Top 22 Canadian cannabis stocks up 127% since Constellation pact, says Stifel
Yesterday's significant outperformance for Canadian cannabis stocks, led by Tilray (TLRY), at one point pushed the total market capitalization for Canadian Licensed Producers above $C80B, before they closed with a combined market cap of C$73B, calculates Stifel analyst Christopher Growe. Since August 15, when Constellation Brands (STZ) announced a pact to invest C$5B into Canopy Growth (CGC), the top 22 Canadian cannabis stocks are up 127% in stock price, noted Growe. A $C73B market cap in relation to what he estimates to be an addressable Canadian market of C$10B is "difficult to fathom," so valuations require global opportunities to be realized, added Growe, who said he questions the pace of development and degree of advantage for these companies. Companies in the cannabis space that can be traded in the U.S. include Aurora Cannabis (ACBFF), CV Sciences (CVSI), Canopy Growth, Cronos Group (CRON) and Tilray.
TLRY Tilray
$109.99

0.98 (0.90%)

10/16/18
BNCH
10/16/18
INITIATION
Target $200
BNCH
Buy
Tilray initiated with a Buy at Benchmark
Benchmark initiated coverage of Tilray with a Buy rating and $200 price target.
10/09/18
COWN
10/09/18
NO CHANGE
Target $172
COWN
Outperform
Tilray price target raised to $172 from $62 at Cowen
Cowen analyst Vivien Azer raised her price target for Tilray (TLRY) to $172 from $62 and keeps an Outperform rating on the shares. The analyst also raised her price target for Outperform-rated Canopy Growth (CGC) to C$82 from C$74.
10/16/18
10/16/18
NO CHANGE
Target $200

Buy
Benchmark starts cannabis stock Tilray at Buy ahead of Canada legalizing
As previously reported, Benchmark analyst Mike Hickey initiated coverage of Tilray with a Buy rating and $200 price target, citing its early leadership in the medical cannabis market in Canada and the upcoming legalization of recreational cannabis, which begins in the North American nation tomorrow. He believes the company's strategic alliance with Novartis (NVS) and supply agreements with Canadian pharmacies that give Tilray a competitive edge in the Canadian medical cannabis market, Hickey tells investors. He also believes the potential international opportunity is "enormous," estimating that the global cannabis market opportunity could exceed $200B over the long-term. Hickey said Tilray is "well-positioned to take a meaningful share of this market."
CRON Cronos Group
$7.96

0.34 (4.46%)

08/15/18
08/15/18
UPGRADE

Hold
Cronos Group upgraded to Hold on 'compelling' new initiatives at Canaccord
As previously reported, Canaccord analyst Matt Bottomley upgraded Cronos Group to Hold from Sell as he believe Cronos has added a number of "compelling" strategic initiatives, such as a supply agreement into Poland's recently legalized medical market; a partnership with MedMen in Canada; the creation of Cronos GrowCo; and the take-or-pay supply agreement with Cura Select of the U.S. Updating for these initiatives lead Bottomley to raise his price target on Cronos shares to C$7.50 from C$6.50.
10/12/18
VERI
10/12/18
INITIATION
VERI
Sell
Cronos Group initiated with a Sell at Veritas
Veritas analyst Stuart Rolfe started coverage of the Canadian Cannabis sector with four Sell ratings, including a Sell on Cronos Group, in a note entitled "End of the Rainbow." The analyst, who sees an intrinsic value of C$4.50 for Cronos shares, said that even assuming 60% of the black market converts, Canada's cannabis industry "looks wildly overvalued."
CANN General Cannabis
$0.00

(0.00%)

IGC India Globalization Capital
$2.69

0.09 (3.46%)

CGC Canopy Growth
$39.00

1.27 (3.37%)

10/17/18
SCOT
10/17/18
INITIATION
SCOT
Sector Perform
Canopy Growth initiated with a Sector Perform at Scotiabank
Scotiabank analyst Oliver Rowe initiated Canopy Growth with a Sector Perform rating and C$61 price target. While Canopy is the dominant Canadian player and global leader in the rapidly evolving cannabis space, giving it a first-mover advantage and potential to be the largest global producer of legal cannabis, he thinks the stock is fully valued. Given its relationship with Constellation Brands (STZ), Rowe believes Canopy is well positioned to enter the cannabis-based beverage market, but he also thinks Canopy ultimately "wants to build brands, not production." Canopy's product development and branding will yield significantly more value for investors than simply an agreement to provide the product, added Rowe.
10/17/18
SCOT
10/17/18
INITIATION
SCOT
Outperform
Scotiabank calls Aphria best play in cannabis, starts with Outperform rating
Scotiabank analyst Oliver Rowe initiated coverage of Aphria (APHQF) with an Outperform rating and C$25 price target. Aphria is building one of the largest cannabis production platforms in Canada and internationally, Rowe tells investors in a research note on the cannabis sector titled "Growing for the Future." He notes the company intends to focus on "perfecting" large-scale production economics to generate high industry margins in the Canadian medical and recreational markets. The analyst views the company as the best way to play the cannabis space in his "limited coverage universe." Rowe this morning also initiated Canopy Growth (CGC) with a Sector Perform rating and C$61 price target. He views the company's growth story as "superb" but finds the valuation full at current share levels.
10/16/18
MSCO
10/16/18
NO CHANGE
Target $259
MSCO
Overweight
Morgan Stanley raises Constellation Brands target to $259 on better beer margins
Morgan Stanley analyst Dara Mohsenian, in a new note to investors, repeated his previously expressed beliefs that the market is not appropriately recognizing Constellation Brands' strong long-term growth prospects in beer and that negative sentiment around the company's investment in Canopy Growth (CGC) has been "overblown." The analyst, who sees scope for material improvement in beer operating margin performance starting in the second half of 2019, reiterates his Overweight rating on Constellation and raised his price target on the shares to $259 from $255.
ACB Aurora Cannabis
$7.12

-0.135 (-1.86%)

CNTTF CannTrust Holdings
$0.00

(0.00%)

TODAY'S FREE FLY STORIES

MYOV

Myovant Sciences

$12.39

-0.465 (-3.62%)

17:18
05/24/19
05/24
17:18
05/24/19
17:18
Syndicate
Breaking Syndicate news story on Myovant Sciences »

Myovant Sciences files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MYOV

Myovant Sciences

$12.39

-0.465 (-3.62%)

17:17
05/24/19
05/24
17:17
05/24/19
17:17
Syndicate
Breaking Syndicate news story on Myovant Sciences »

Myovant Sciences files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVS

Novartis

$87.49

3.03 (3.59%)

, QGEN

Qiagen

$38.22

-0.255 (-0.66%)

16:57
05/24/19
05/24
16:57
05/24/19
16:57
Hot Stocks
Qiagen launches diagnostic for PIK3CA biomarkers in breast cancer »

Qiagen (QGEN) announced…

NVS

Novartis

$87.49

3.03 (3.59%)

QGEN

Qiagen

$38.22

-0.255 (-0.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

  • 31

    May

  • 20

    Jun

  • 06

    Aug

AVH

Avianca

$3.96

0.91 (29.84%)

16:56
05/24/19
05/24
16:56
05/24/19
16:56
Periodicals
ANAC suspends flights, operations of Avianca Brasil, Reuters reports »

Brazil's ANAC said…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$179.03

-0.64 (-0.36%)

16:53
05/24/19
05/24
16:53
05/24/19
16:53
Periodicals
Apple acquires startup Tueo Health, CNBC reports »

Apple has bought Tueo…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Jun

SHSP

SharpSpring

$16.37

-0.24 (-1.44%)

16:52
05/24/19
05/24
16:52
05/24/19
16:52
Syndicate
Breaking Syndicate news story on SharpSpring »

SharpSpring files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Jun

CREG

China Recycling Energy

$0.48

0.005 (1.05%)

16:41
05/24/19
05/24
16:41
05/24/19
16:41
Syndicate
Breaking Syndicate news story on China Recycling Energy »

China Recycling Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FENC

Fennec

$3.88

(0.00%)

16:36
05/24/19
05/24
16:36
05/24/19
16:36
Conference/Events
Fennec management to meet with Wedbush »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 18

    Jun

TD

Toronto-Dominion

$56.66

0.65 (1.16%)

16:35
05/24/19
05/24
16:35
05/24/19
16:35
Syndicate
Breaking Syndicate news story on Toronto-Dominion »

Toronto-Dominion files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:30
05/24/19
05/24
16:30
05/24/19
16:30
Options
Preliminary option volume of 15.7M today »

Preliminary option volume…

CBUS

Cibus

$0.00

(0.00%)

16:25
05/24/19
05/24
16:25
05/24/19
16:25
Syndicate
Cibus requests withdrawal of registration statement »

The company's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$355.14

4.57 (1.30%)

16:23
05/24/19
05/24
16:23
05/24/19
16:23
Periodicals
Boeing 737 MAX return delayed by FAA expanding review, WSJ reports »

A review of Boeing's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 05

    Jun

FB

Facebook

$181.03

0.14 (0.08%)

, BA

Boeing

$355.14

4.57 (1.30%)

16:20
05/24/19
05/24
16:20
05/24/19
16:20
On The Fly
Fly Intel: Wall Street's top stories for Friday »

U.S. stocks, which had a…

FB

Facebook

$181.03

0.14 (0.08%)

BA

Boeing

$355.14

4.57 (1.30%)

UAL

United Continental

$80.77

-0.14 (-0.17%)

SMI

SMIC

$5.23

-0.26 (-4.74%)

HPQ

HP Inc.

$20.03

0.835 (4.35%)

HPE

HP Enterprise

$14.36

0.03 (0.21%)

NVS

Novartis

$87.49

3.03 (3.59%)

CNC

Centene

$56.84

1.39 (2.51%)

WCG

WellCare

$275.45

0.99 (0.36%)

TSS

TSYS

$113.42

13.81 (13.86%)

GPN

Global Payments

$153.42

5.45 (3.68%)

HIBB

Hibbett Sports

$23.91

4.07 (20.51%)

DVAX

Dynavax

$5.77

-0.59 (-9.28%)

FL

Foot Locker

$44.39

-8.455 (-16.00%)

SPLK

Splunk

$119.13

-9.55 (-7.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

  • 24

    May

  • 29

    May

  • 30

    May

  • 30

    May

  • 30

    May

  • 31

    May

  • 03

    Jun

  • 05

    Jun

  • 05

    Jun

  • 05

    Jun

  • 06

    Jun

  • 07

    Jun

  • 08

    Jun

  • 09

    Jun

  • 10

    Jun

  • 13

    Jun

  • 14

    Jun

  • 24

    Jun

  • 24

    Jun

  • 09

    Jul

  • 09

    Jul

  • 23

    Jul

  • 13

    Nov

VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

16:20
05/24/19
05/24
16:20
05/24/19
16:20
Options
Closing CBOE SPX and VIX Index summary for May 24th »

The CBOE Volatility Index…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

16:17
05/24/19
05/24
16:17
05/24/19
16:17
Technical Analysis
NASDAQ market internals summary »

Volume was average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

16:16
05/24/19
05/24
16:16
05/24/19
16:16
Technical Analysis
NYSE market internals summary »

Volume was below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RHE

Regional Health Properties

$2.06

0.09 (4.57%)

16:15
05/24/19
05/24
16:15
05/24/19
16:15
Hot Stocks
Regional Health Properties receives NYSE notice over late Form 10-Q filing »

Regional Health…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TBIO

Translate Bio

$9.12

-0.09 (-0.98%)

16:14
05/24/19
05/24
16:14
05/24/19
16:14
Syndicate
Breaking Syndicate news story on Translate Bio »

Translate Bio files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

TEAM

Atlassian

$129.57

2.33 (1.83%)

16:11
05/24/19
05/24
16:11
05/24/19
16:11
Hot Stocks
Atlassian co-CEOs adopt new 10b5-1 trading plans »

Atlassian announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jun

  • 10

    Jun

HIBB

Hibbett Sports

$23.90

4.06 (20.46%)

16:10
05/24/19
05/24
16:10
05/24/19
16:10
Recommendations
Hibbett Sports analyst commentary  »

Hibbett Sports price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

MYOV

Myovant Sciences

$12.44

-0.415 (-3.23%)

16:09
05/24/19
05/24
16:09
05/24/19
16:09
Earnings
Myovant Sciences reports Q4 EPS ($1.07), consensus ($1.02) »

Cash and cash equivalents…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TD

Toronto-Dominion

$56.66

0.65 (1.16%)

16:06
05/24/19
05/24
16:06
05/24/19
16:06
Periodicals
TD Bank's Masrani says trade tensions put confidence at risk, Bloomberg says »

In an interview with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CPRT

Copart

$71.06

1.07 (1.53%)

16:02
05/24/19
05/24
16:02
05/24/19
16:02
Recommendations
Copart analyst commentary  »

Outlook for Copart…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Jun

PFE

Pfizer

$41.96

0.04 (0.10%)

16:01
05/24/19
05/24
16:01
05/24/19
16:01
Hot Stocks
Pfizer says Phase 3 study of LYRICA did not meet primary endpoint »

Pfizer announced that a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

IMMR

Immersion

$7.69

-0.03 (-0.39%)

15:55
05/24/19
05/24
15:55
05/24/19
15:55
Options
Immersion put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.